Results 221 to 230 of about 710,185 (341)

Pulmonary arterial hypertension with cardiopulmonary comorbidities: is it a unique phenotype? [PDF]

open access: yesBMC Pulm Med
Zhang M   +21 more
europepmc   +1 more source

Availability, use, efficacy and safety of bevacizumab in European hereditary haemorrhagic telangiectasia centres

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Introduction Bevacizumab, a vascular endothelial growth factor inhibitor, is used off‐label for treatment of severe anaemia related to epistaxis, gastrointestinal bleeding and/or severe hepatic arteriovenous malformations (HAVM) and right‐sided cardiac failure in patients with hereditary haemorrhagic telangiectasia (HHT).
Pernille D. Haahr   +18 more
wiley   +1 more source

Cilostazol Therapy Attenuates Monocrotaline-Induced Pulmonary Arterial Hypertension in Rat Model

open access: diamond, 2008
Li‐Teh Chang   +7 more
openalex   +2 more sources

An experimental medicine protocol for exploring the haemodynamic effects of dual agonism at the glucagon‐like peptide‐1 and glucagon receptor in healthy subjects

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims Glucagon‐like peptide‐1 (GLP‐1) and glucagon dual receptor agonists are in clinical development for a range of metabolic conditions, including type 2 diabetes and obesity. The cardiovascular actions at these receptors are well studied, but less is known about their combination.
James Goodman   +13 more
wiley   +1 more source

Clinical efficacy and survival with first-line inhaled iloprost therapy in patients with idiopathic pulmonary arterial hypertension [PDF]

open access: bronze, 2005
Christian Opitz   +11 more
openalex   +1 more source

Gender differences in the antihypertensive effect after radiofrequency denervation of the renal arteries in resistant arterial hypertension

open access: hybrid, 2023
E. V. Mikova   +6 more
openalex   +2 more sources

Nonadherence and uncontrolled arterial hypertension in Croatia—Insights from the May Measurement Month 2023 campaign and Hunting the silent killer programme

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims To determine the prevalence of non‐adherence to antihypertensive medicines and to identify demographic and behavioral factors associated with non‐adherence in subjects enrolled in the May Measurement Month (MMM) 2023, as part of the permanent public health action Hunting the silent killer.
Valerija Bralić Lang   +12 more
wiley   +1 more source

Home - About - Disclaimer - Privacy